{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2022-09-22&answer.answeringMemberConstituency=Newark&max-answer.questionFirstAnswered.=2022-09-27T14%3A47%3A20.387Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answer.dateOfAnswer=2022-09-22&answer.answeringMemberConstituency=Newark&max-answer.questionFirstAnswered.=2022-09-27T14%3A47%3A20.387Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2022-09-22&answer.answeringMemberConstituency=Newark&_metadata=all&max-answer.questionFirstAnswered.=2022-09-27T14%3A47%3A20.387Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answer.dateOfAnswer=2022-09-22&answer.answeringMemberConstituency=Newark&max-answer.questionFirstAnswered.=2022-09-27T14%3A47%3A20.387Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2022-09-22&answer.answeringMemberConstituency=Newark&max-answer.questionFirstAnswered.=2022-09-27T14%3A47%3A20.387Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2022-09-22&answer.answeringMemberConstituency=Newark&max-answer.questionFirstAnswered.=2022-09-27T14%3A47%3A20.387Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1506237", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1506237/answer", "answerText" : {"_value" : "<p>The information requested on clinical trials hosted in Wales and Scotland is not held centrally. A table showing the number of phase one, two and three clinical trials supported by the National Institute for Health and Social Care Research Clinical Research Network in England for dementia from 2012/13 to 2021/22 is attached.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "attachment" : {"_about" : "http://data.parliament.uk/resources/1506237/answer/attachment/1", "fileName" : {"_value" : "Formatted TABLE PQ 49792 attachment.docx"}
          , "title" : "Dementia clinical trials in England 2012 to 2022"}
        , "dateOfAnswer" : {"_value" : "2022-09-22", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "49792"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-09-22T08:33:32.573Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Dementia: Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many (a) phase I, (b) phase II and (c) phase III clinical trials for dementia have been hosted in Wales in each of the last 10 years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4476", "label" : {"_value" : "Biography information for Dr James Davies"}
      }
      , "tablingMemberConstituency" : {"_value" : "Vale of Clwyd"}
      , "tablingMemberPrinted" : [{"_value" : "Dr James Davies"}
      ], "uin" : "49731"}
    , {"_about" : "http://data.parliament.uk/resources/1506384", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1506384/answer", "answerText" : {"_value" : "<p>The information requested on clinical trials hosted in Wales and Scotland is not held centrally. A table showing the number of phase one, two and three clinical trials supported by the National Institute for Health and Social Care Research Clinical Research Network in England for dementia from 2012/13 to 2021/22 is attached.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "attachment" : {"_about" : "http://data.parliament.uk/resources/1506384/answer/attachment/1", "fileName" : {"_value" : "Formatted TABLE PQ 49792 attachment.docx"}
          , "title" : "Dementia clinical trials in England 2012 to 2022"}
        , "dateOfAnswer" : {"_value" : "2022-09-22", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "49731"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-09-22T08:33:32.527Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Dementia: Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care how many (a) phase one, (b) phase two and (c) phase three clinical trials for dementia treatments have taken place in (i) England, (ii) Wales, and (iii) Scotland in each of the past 10 years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4782", "label" : {"_value" : "Biography information for Neale Hanvey"}
      }
      , "tablingMemberConstituency" : {"_value" : "Kirkcaldy and Cowdenbeath"}
      , "tablingMemberPrinted" : [{"_value" : "Neale Hanvey"}
      ], "uin" : "49792"}
    , {"_about" : "http://data.parliament.uk/resources/1505830", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1505830/answer", "answerText" : {"_value" : "<p>The Government has decided not to procure Evusheld for prevention through emergency routes at this time. This is a decision based on independent clinical advice by the multi-agency RAPID C-19 and a national expert policy working group, which considered a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies. It concluded that there is currently insufficient evidence of benefit to recommend deployment at this time. \u202fThe Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and agrees that it should now be referred to the National Institute for Health and Care Excellence for further evaluation.<\/p><p> <\/p><p>The Department wrote to patient groups on 5 September 2022 with information on this decision and evidence considered. The Department intends to publish further details of the clinical advice received shortly.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-09-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-09-22T13:56:17.48Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Tixagevimab/cilgavimab"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment the UK Health Security Agency of the effectiveness of the drug Evusheld against the Omicron variant of covid-19; and if she will make that treatment available on the NHS to people who are immunocompromised.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4859", "label" : {"_value" : "Biography information for Virginia Crosbie"}
      }
      , "tablingMemberConstituency" : {"_value" : "Ynys Môn"}
      , "tablingMemberPrinted" : [{"_value" : "Virginia Crosbie"}
      ], "uin" : "49297"}
    , {"_about" : "http://data.parliament.uk/resources/1505868", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1505868/answer", "answerText" : {"_value" : "<p>We replied to the hon. Member on 19 August 2022.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-09-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-09-22T14:01:42.08Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Members: Correspondence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, when she plans to respond to the letter of 24 June 2022 from the hon. member for West Lancashire on staffing levels in clinical radiology and clinical oncology, reference ZA60022.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Lancashire"}
      , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
      ], "uin" : "49103"}
    , {"_about" : "http://data.parliament.uk/resources/1505900", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1505900/answer", "answerText" : {"_value" : "<p>We plan to publish the public consultation on the draft legislation which will enable the General Medical Council (GMC) to regulate physician associates (PAs) and anaesthesia associates (AAs) in the autumn. Following this consultation, we will finalise the legislation to be laid in the second half of 2023, subject to Parliamentary time. The GMC will then develop and implement its rules and processes for regulating PAs and AAs within 12 months, enabling regulation to commence in the second half of 2024.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-09-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-09-22T13:42:47.323Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Anaesthesia Associates and Physician Associates: Regulation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 6 June 2022 to Question 7493 on Anaesthesia Associates and Physician Associates: Regulation, if she will set out a timetable for bringing forward legislative proposals on the regulation of physician associates and anaesthesia associates; and if she will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1548", "label" : {"_value" : "Biography information for Jessica Morden"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newport East"}
      , "tablingMemberPrinted" : [{"_value" : "Jessica Morden"}
      ], "uin" : "49105"}
    , {"_about" : "http://data.parliament.uk/resources/1506037", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1506037/answer", "answerText" : {"_value" : "<p>There are three main types of stoma related to the digestive and urinary system: colostomy, ileostomy, and urostomy.<\/p><p> <\/p><p>The following table shows a count of completed surgical procedures for colostomy, ileostomy and urostomy undertaken within all National Health Service-funded hospital providers in England from 2017/18 to 2020/21. This does not represent a count of people, as the same person could have the same procedure on more than one occasion.<\/p><p>2017/18 2018/19 2019/20 2020/21<\/p><p>Colostomy 593 547 498 418<\/p><p>Ileostomy 563 498 472 451<\/p><p>Urostomy 2,013 1,856 1,784 1,020<\/p><p>Total 3,169 2,901 2,754 1,889<\/p><p>Source: NHS Digital, Hospital Episode Statistics<\/p><p>Some stomas are temporary and can be reversed. This data shows the total numbers that were introduced across the period. However, some of these may subsequently have been reversed. Data at a sub-national level has disclosure controls applied to protect patient confidentiality.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-09-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-09-22T13:50:22.927Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Gastrointestinal System: Surgery"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what data the Government holds on the (a) number and distribution of stomas across the UK and (b) type of stoma and patient need; and what those figures and details are for the North East.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "49137"}
    , {"_about" : "http://data.parliament.uk/resources/1506046", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1506046/answer", "answerText" : {"_value" : "<p>Data on the Federated Data Platform (FDP) will be transferred from existing data sets, which have a lawful basis for collection and processing. Therefore, seeking the consent of individuals for the transfer of these datasets will not be required. NHS England is committed to transparency on the way data is used within the FDP to ensure that patients are informed of the choice to opt out, where applicable and how to do so. It is also committed to publishing information on who is accessing data and for what purpose.<\/p><p>Data protection law and the common law duty of confidentiality will continue to apply. There must always be a valid lawful basis for the collection and processing of personal information, with transparency about the use of data within federated data platforms, as defined under the applicable legislation. The FDP will be used as separate instances to provide access to data for both the primary use of data, such as direct patient care and the secondary use of data, such as its use in analysis and planning. This will be based on specific use cases which set out the data specification and data classification and access controls which will be used. Where confidential patient information is being used to support direct care within the FDP, explicit consent would not be required as this data has implied consent for use.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-09-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-09-22T13:43:05.93Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "NHS: Database"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if the Government will introduce provisions to ensure that meaningful and informed consent is sought from each patient before any of their health or social care data is transferred onto the Federated Data Platform.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "49205"}
    , {"_about" : "http://data.parliament.uk/resources/1505283", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1505283/answer", "answerText" : {"_value" : "<p>There are no current plans to review or extend the National Health Service prescription charge medical exemptions to include people who have received an organ transplant. For those ineligible for an exemption on medical grounds, arrangements are in place to assist with the affordability of prescriptions, including exemptions for which people with a long-term medical condition may already qualify. Approximately 89% of NHS prescription items are dispensed in the community free of charge.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-09-22", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "47716"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-09-22T15:08:57.277Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-06", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prescriptions: Fees and Charges"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of extending prescription charge exemptions to patients requiring lifelong medication following an organ transplant.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4869", "label" : {"_value" : "Biography information for Nadia Whittome"}
      }
      , "tablingMemberConstituency" : {"_value" : "Nottingham East"}
      , "tablingMemberPrinted" : [{"_value" : "Nadia Whittome"}
      ], "uin" : "48526"}
    , {"_about" : "http://data.parliament.uk/resources/1505426", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1505426/answer", "answerText" : {"_value" : "<p>In July 2019, a pilot project was launched to develop and test a \u2018subscription-style\u2019 evaluation and payment model for antibiotics in England, which would pay pharmaceutical companies for access to antibiotics based on its value to the National Health Service, rather than the volume used. This payment model aims to incentivise pharmaceutical companies to develop new antimicrobials, despite the potential for the use of newly developed antibiotics to be \u2018held back\u2019 to protect against the threat of antimicrobial resistance.<\/p><p>Payments from NHS England to the two pharmaceutical companies involved in the pilot commenced on 1 July 2022. Officials are now considering how to develop the new frameworks for the evaluation and payment of new antimicrobials, including through consultation with domestic and international stakeholders. The consultation process will continue until spring 2023.<\/p><p>In June 2022, the previous Secretary of State for Health and Social Care (the Rt hon. Steve Barclay MP) invited health ministers in Scotland, Wales and Northern Ireland to engage in this process and assist in the evolution of this model. The devolved administrations have agreed in principle and officials in the United Kingdom will finalise the details of each nation\u2019s participation. It will be for each devolved administration to decide if or how any agreed frameworks are implemented in their health system.<\/p><p>To support the adoption of similar models in other countries, findings from the pilot project have been published online and shared at international conferences. The Government has also advocated for such models internationally, such as during the UK\u2019s 2021 G7 Presidency, where health and finance ministers have committed to explore options to bring new antimicrobials to market.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-09-22", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "48426"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-09-22T15:19:10.46Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-06", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Antimicrobials: Procurement"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking to develop a UK-wide policy for the purchase and evaluation of antimicrobials following the announcement of a subscription deal for two antimicrobials for the NHS in England; what timeframe has been agreed for that process; and what opportunities will be in place for (a) the UK and (b) international stakeholders to contribute to that process.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"}
      }
      , "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"}
      , "tablingMemberPrinted" : [{"_value" : "Martyn Day"}
      ], "uin" : "48425"}
    , {"_about" : "http://data.parliament.uk/resources/1505429", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1505429/answer", "answerText" : {"_value" : "<p>In July 2019, a pilot project was launched to develop and test a \u2018subscription-style\u2019 evaluation and payment model for antibiotics in England, which would pay pharmaceutical companies for access to antibiotics based on its value to the National Health Service, rather than the volume used. This payment model aims to incentivise pharmaceutical companies to develop new antimicrobials, despite the potential for the use of newly developed antibiotics to be \u2018held back\u2019 to protect against the threat of antimicrobial resistance.<\/p><p>Payments from NHS England to the two pharmaceutical companies involved in the pilot commenced on 1 July 2022. Officials are now considering how to develop the new frameworks for the evaluation and payment of new antimicrobials, including through consultation with domestic and international stakeholders. The consultation process will continue until spring 2023.<\/p><p>In June 2022, the previous Secretary of State for Health and Social Care (the Rt hon. Steve Barclay MP) invited health ministers in Scotland, Wales and Northern Ireland to engage in this process and assist in the evolution of this model. The devolved administrations have agreed in principle and officials in the United Kingdom will finalise the details of each nation\u2019s participation. It will be for each devolved administration to decide if or how any agreed frameworks are implemented in their health system.<\/p><p>To support the adoption of similar models in other countries, findings from the pilot project have been published online and shared at international conferences. The Government has also advocated for such models internationally, such as during the UK\u2019s 2021 G7 Presidency, where health and finance ministers have committed to explore options to bring new antimicrobials to market.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-09-22", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "48425"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-09-22T15:19:10.507Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-09-06", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Antimicrobials: Procurement"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if her Department will take steps to ensure that the template for a subscription model for the purchase and evaluation of antimicrobials, following a deal for the NHS in England, can be adopted by other countries.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"}
      }
      , "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"}
      , "tablingMemberPrinted" : [{"_value" : "Martyn Day"}
      ], "uin" : "48426"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&answer.dateOfAnswer=2022-09-22&answer.answeringMemberConstituency=Newark&max-answer.questionFirstAnswered.=2022-09-27T14%3A47%3A20.387Z", "page" : 0, "startIndex" : 1, "totalResults" : 45, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}